Donate

Ensemble on Track with Autoimmune Disease Treatment

Home»Health»Intestinal Disease»Crohns»Ensemble on Track with Autoimmune Disease Treatment

Ensemble on Track with Treatment

Small molecule therapeutics developer Ensemble Therapeutics reported positive preclinical data of its small molecule Interleukin-17 (IL-17) antogonist, which puts the company on track to nominate a drug candidate for clinical development in 2013.

The Cambridge-based company said its Ensemblins have strong oral activity as antagonists of IL-17, a cytokline shown in diseases such as psoriasis, , Crohn’s disease and . Ensemble Senior Vice President of Biology David Livingston presented the data during a presentation of its data at the annual meeting of the American College of Rheumatology (ACR) taking place in Washington, DC this week.

 

Read Full Report


Mass High Tech
Ensemble on track with autoimmune disease treatment
Mass High Tech
The Cambridge-based company said its Ensemblins have strong oral activity as antagonists of IL-17, a cytokline shown in diseases such as , rheumatoid arthritis, Crohn’s disease and inflammatory bowel disease. Ensemble Senior Vice President of
Ensemble Therapeutics Presents Oral Efficacy of First-in-Class Small Molecule MarketWatch (press release)all 6 news articles »

You must be logged in to post a comment Login

No Guts Know Glory

IDEAS Kids

IDEAS Kids

IBD Adventures